| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HLA-DOA |
| Uniprot No | P06340 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-217aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSTKADHMG SYGPAFYQSY GASGQFTHEF DEEQLFSVDL KKSEAVWRLP EFGDFARFDP QGGLAGIAAI KAHLDILVER SNRSRAINVP PRVTVLPKSR VELGQPNILI CIVDNIFPPV INITWLRNGQ TVTEGVAQTS FYSQPDHLFR KFHYLPFVPS AEDVYDCQVE HWGLDAPLLR HWELQVPIPP PDAME |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HLA-DOA重组蛋白的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**：*Expression and Purification of Recombinant HLA-DOA for Structural Studies*
**作者**：Smith J, et al.
**摘要**：该研究报道了在昆虫细胞表达系统中重组表达HLA-DOA蛋白的优化方法，通过亲和层析纯化获得高纯度蛋白，并利用X射线晶体学初步解析其结构，为后续功能研究提供基础。
2. **文献名称**：*Functional Characterization of HLA-DOA in Antigen Presentation Using Recombinant Protein*
**作者**：Lee S, et al.
**摘要**：通过大肠杆菌表达系统制备重组HLA-DOA蛋白，研究其与特定肽段的结合能力及在抗原呈递中的作用，发现HLA-DOA可能通过调控MHC II类分子的组装影响免疫应答。
3. **文献名称**：*HLA-DOA Polymorphisms and Autoimmune Disease Association Analyzed via Recombinant Protein Assays*
**作者**：Garcia R, et al.
**摘要**：利用哺乳动物细胞表达的重组HLA-DOA蛋白，分析其不同遗传变异体与自身免疫疾病(如类风湿性关节炎)的关联，揭示特定单体型可能通过改变蛋白构象参与疾病发生。
---
**注**：以上文献为示例性质，实际引用时需核实数据库(如PubMed、Web of Science)中的真实论文信息。如需进一步扩展，可结合关键词“HLA-DOA recombinant protein expression/purification/function”检索最新研究。
HLA-DOA, a member of the human leukocyte antigen (HLA) class II family, is encoded by the HLA-DOA gene located on chromosome 6p21.3. As a non-classical MHC class II molecule, it forms a heterodimer with HLA-DOB, distinct from classical HLA-DP, -DQ, and -DR heterodimers involved in antigen presentation. Unlike these classical molecules, HLA-DOA exhibits limited polymorphism and shows restricted tissue expression, primarily in antigen-presenting cells like B lymphocytes and dendritic cells.
The HLA-DOA/DOB complex functions as a regulatory chaperone for classical HLA class II molecules. It modulates peptide loading and MHC II trafficking in late endosomal compartments, influencing antigen presentation efficiency. Structural studies reveal its similarity to classical MHC II proteins but with key differences in the peptide-binding groove, explaining its inability to present antigens conventionally.
Recombinant HLA-DOA protein, typically produced in mammalian expression systems (e.g., HEK293 or CHO cells), preserves post-translational modifications critical for structural integrity. Its production enables functional studies investigating immune regulation mechanisms, particularly in balancing immune activation and tolerance. Researchers utilize purified HLA-DOA in binding assays, crystallography, and cellular interaction studies to decipher its role in autoimmune diseases, infectious immunity, and transplant rejection. Recent interest focuses on its potential as a therapeutic target for immune modulation and biomarker in lymphoproliferative disorders.
×
